Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd.

TTPEX:6576
70.60
TWD
-0.90
(-1.26%)
0.14EPS
561.91P/E
12.73BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.29
0.3
0.78
2.25
1.9
2.55
1.53
3.05
2.78
3.01
Basic EPS, GAAP
-4.93
-5.76
-4.12
-5.41
-6.37
-5.02
-4.98
-4.8
-4
-8.14
-7.87
-5.7
0.14
Free Cash Flow per Basic Share
54.91
-8.38
-3.75
-6.67
-6.61
-6.39
-6.85
-1.86
-2.47
-7.34
-9.68
-5.54
-3.83
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.6
4.91
7.08
7.2
5.39
8.69
15.47
11.07
7.62
9.16
10.33
5.9
8.08
Tangible Book Value per Share
0.6
4.25
6.54
6.11
3.49
6.33
13.7
9.77
6.44
8.23
9.57
5.2
7.43
Basic Weighted Avg Shares
2
57
75
82
87
97
103
119
118
127
137
155
156
Sales/Revenue/Turnover
- -
- -
- -
24
26
75
230
226
302
195
419
431
471
Operating Margin (%)
- -
- -
- -
-1,867.17
-2,093.26
-625.18
-210.38
-238.3
-155.7
-516.63
-257.9
-199.95
-104.5
Depreciation Expense
1
6
9
13
17
39
49
51
51
74
81
68
56
Net Income, GAAP
-8
-331
-309
-443
-552
-487
-511
-569
-473
-1,036
-1,081
-883
22
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
74.79
Profit Margin (%)
- -
- -
- -
-1,869.28
-2,118.28
-647.91
-221.63
-251.86
-156.76
-531.33
-258.2
-204.78
4.77
Working Capital
32
289
407
480
194
489
1,565
1,229
786
1,120
1,424
699
1,028
LT Debt
- -
- -
- -
- -
- -
3
70
6
26
13
93
21
384
Total Equity
42
345
539
604
499
896
1,829
1,320
911
1,245
1,599
930
1,273
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8.52
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.7
Return on Common Equity (%)
- -
-170.72
-69.76
-77.6
-100.07
-69.88
-37.48
-36.15
-42.37
-96.17
-76.04
-69.85
2

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
211
14
14
LT Borrowings
- -
368
371
LT Finance Leases
21
17
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
158
158
158
Market Capitalization
12,698
12,068
12,729

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
986
1,225
1,157
Cash, Cash Equivalents & STI
700
892
911
Accounts Receivable, Net
43
81
56
Inventories
145
140
163
Total Current Liabilities
286
90
129
Payables & Accruals
- -
- -
- -
ST Debt
211
14
14
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.91%
-7.11%
-41.86%
Free Cash Flow
27.01%
38.15%
-35.49%
Net Income, GAAP
15.43%
19.95%
-18.31%
Sales/Revenue/Turnover
- -
22.77%
3.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
94
80
141
419
2025
110
112
157
52
431
2026
80
182
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.88
-1.21
-2.25
-3.52
-7.87
2025
-1.9
-2.14
-0.74
-0.93
-5.7
2026
2.59
-0.79
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Benjamin Chien
Full Time Employees
1,760
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 19-3, Sanchong Road Taipei TPE Taiwan 115
IPO Date
Jun 29, 2018
Business
Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576) develops and commercializes biopharmaceutical products focused on stabilized injectable formulation (SIF) long-acting injectable technologies and novel chemical entity (NCE) programs targeting specialty markets, rare diseases, oncology, respiratory disorders, neurology, and high unmet medical needs; its core SIF pipeline includes CAMCEVI (leuprolide mesylate, FP-001) 42 mg and 21 mg approved in the US, Canada, and EU for advanced prostate cancer and launched in the US, with ongoing Phase 3 trials for central precocious puberty and premenopausal breast cancer, FP-014 (triptorelin) in Phase 3 for prostate cancer, FP-016 and FP-017 (undisclosed) for neurology/psychiatry; its NCE portfolio features Aderamastat (FP-025, MMP-12 inhibitor) with Phase 2 proof-of-concept in allergic asthma completed positively and planned for cardiac sarcoidosis, Linvemastat (FP-020, MMP-12 inhibitor) in Phase 2 for asthma/COPD and inflammatory bowel disease, Mirivadelgat (FP-045, ALDH2 activator) in Phase 2 for pulmonary hypertension associated with interstitial lung disease, alongside earlier-stage MMP-12 inhibitors for idiopathic pulmonary fibrosis and neurology, and ALDH2 activators for cardiovascular, renal, metabolic diseases, and neurology. Founded in 2013 and headquartered in Taipei, Taiwan, with US operations, the company conducts R&D and clinical activities in the United States, China, and Europe, serving endocrinology, oncology, respiratory, and rare disease patient populations through proprietary SIF-ADAGIO, SIF-LEGATO, SIF-DUO, and SIF-MEZZO platforms. Recent developments include the completion of a US$42.1 million public financing in December 2024 to advance FP-014 Phase 3 trials, FP-020 Phase 2 studies in asthma and IBD, and FP-045 Phase 2 in PH-ILD; progression of CAMCEVI expansions and NCE programs such as FP-025 positive Phase 2 outcomes; and strategic partnerships including GeneScience Pharmaceuticals for CAMCEVI in China.